Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Septoplasty versus non-surgical management for nasal obstruction in adults with a deviated septum: economic evaluation alongside a randomized controlled trial

Fig. 3

a Acceptability curve illustrating the probability that septoplasty is cost-effective from a healthcare perspective (y-axis) at different cost-effectiveness thresholds (x-axis) after 12 months (dashed line) and 24 months (solid line). Against a threshold of €20,000 per QALY, septoplasty was cost-effective in 7% of the replications after 12 months and in 56% of the replications after 24 months. b Acceptability curve illustrating the probability that septoplasty is cost-effective from a societal perspective (y-axis) at different cost-effectiveness thresholds (x-axis) after 12 months (dashed line) and 24 months (solid line). Against a threshold of €20,000 per QALY, septoplasty was cost-effective in 0% of the replications after 12 months and in 25% of the replications after 24 months

Back to article page